Parkinson's Disease
Conditions
Keywords
Parkinson's disease, Isradipine, Neuroprotection
Brief summary
The objective of this study is to establish the safety and tolerability of isradipine, sustained release preparation in patients with PD. This study is a logical continuation of the project that is being completed now and is conducted in preparation to NIH submission of the pivotal study on the efficacy of this agent for neuroprotection in PD. This study is conducted in parallel with Dr. Surmeier's work on further development of the preclinical data. The focus of his work now is to establishing the correlation between the dose that demonstrated neuroprotective effect in animal model and the dose used for clinical practice. Hypothesis 1: Patients with PD will be able to tolerate isradipine across the FDA recommended dose range. We expect 10% attrition due to hypotensive effect of the agent. Hypothesis 2: Patients with PD and concomitant stable hypertension will be able to tolerate isradipine provided that the dose of the concomitant antihypertensive agent is adjusted based on the blood pressure reading.
Detailed description
Isradipine safety profile Isradipine, FDA approved for treatment of hypertension since 1990, has a well established data on its efficacy and safety in the hypertensive population (see package insert, Appendix 3). The side effect profile of isradipine is related to the primary mechanism of action of the agent as a vasodilator of the vascular smooth muscles and myocardium, and includes hypotension, bradycardia, weakness, and syncope. As per package insert, the most common adverse effects are headache (13.7% with active treatment versus 14% placebo), dizziness (7.3 vs 4.4) and peripheral edema as reflection of the vasodilatory effect which is dose dependent with incidence of about 3.5% at 5 mg, 8.7% at 10 mg and 8.5% at 20 mg. Of note the incidence of edema is substantially lower compared to CR preparation (9:13:36% for the respective doses). The other side effects include angina, asthenia, flushing, heart failure, and palpitations. According to the package insert, the adverse effects are usually not serious, dose dependent, and respond well to dose reduction or discontinuation of therapy. Isradipine has no effect on atrioventricular or sinoatrial conduction. The only absolute contraindications for isradipine are hypersensitivity to DHP compounds and hypotension defined as systolic blood pressure below 90 mm Hg. Until our studies, isradipine has not been tested in the PD population.
Interventions
DRUGDynacirc CR (Isradipine)
Dynacirc CR is given by the recommended schedule for titration. Subjects start on a 5mg dose and are increased in increments of 5mg every 2 weeks provided that the subjects do not have significant adverse events or symptomatic orthostatic hypotension.
Sponsors
Northwestern Memorial Hospital
Northwestern University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with idiopathic Parkinson's disease age 30-75 2. Hoehn and Yahr stage \<2.5 3. PD duration less than 5 years 4. For the subjects treated with PD medications, the regimen has to be stable for \>1 month prior to enrollment
Exclusion criteria
1. Atypical Parkinsonian syndrome 2. Patients with history of stable hypertension treated with other antihypertensive agents will be allowed provided that the doses of concomitant anti HTN therapy can be reduced/adjusted during the study based on the BP readings. The number of concomitant antihypertensive agents should not exceed two. The dose of concomitant antihypertensive agents has to be stable for \> 1 month 3. Presence of orthostatic hypotension at the screening visit defined as \> 20 mmHg change in systolic BP and 10mm change in diastolic BP after 2 min of standing, or baseline BP \<90/60. 4. Presence of other medical conditions that in the opinion of the investigator will preclude safe use of the drug. 5. Presence of cognitive dysfunction as determined by MMSE score \<24 6. Failure to sign the informed consent 7. Inability to cooperate with the study procedures 8. Presence of motor fluctuations 9. History of bradycardia defined as heart rate \< 55 10. Women of childbearing potential who are not surgically sterilized have to use a reliable measure of contraception and have a negative urine pregnancy test at screening 11. Participation in other investigational drug trials within 30 days prior to screening 12. History of brain surgery for Parkinson's Disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tolerability of Isradipine Based on the Number of Participants That Complete the Study | 1 year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants That Tolerated Each Dose of Isradipine | 1 year | Tolerability= maximum tolerated dose |
| Number of Participants That Tolerated Each Dose Level of Isradipine Between PD Patients Treated With Antihypertensive Agent and Not on Antihypertensive Agent | 1 year | At the time of enrollment, some patients were currently being treated with antihypertensive agents including Propanolol, Toprol, Lisinopril, Diovan, Norvasc. HTN+: Participants on an antihypertensive agent HTN-: Participants not on an antihypertensive agent |
| Safety of the Standard Titration Schedule in PD Population as Measured by the Number of Patients That Are Able to Increase the Dose to 20 mg Daily | 1 year | — |
| Change in Motor UPDRS Scores: Baseline vs. Final Visit | 12 weeks | Baseline visit = Week 0 Final visit = Week 12 Unified Parkinson's Disease Rating Scale (UPDRS)is made up of the following sections: Part I: evaluation of Mentation, behavior, and mood Part II: self evaluation of the activities of daily life Part III: clinician-scored motor evaluation Part IV: Hoehn and Yahr stating of severity of Parkinson disease. Part V: Schwab and England ADL scale Only part three was used for this assessment. The higher the UPDRS score, the greater the disability from PD. The range for scores for Section III is 0 to 108. |
| Pharmacokinetic Data - Mean Serum Concentration and Dosage Exposure Across the Dose Range of Isradipine | 1 year | Mean Plasma Concentration (+/- SD ng/mL) |
| Number of Participants That Completed the Study at Each Dose Level of Isradipine | 1 year | — |
Countries
United States
Participant flow
Pre-assignment details
35 Screened
Participants by arm
| Arm | Count |
|---|---|
| Isradipine 20mg, 15mg, 10mg or 5 mg | 31 |
| Total | 31 |
Baseline characteristics
| Characteristic | Isradipine 20mg, 15mg, 10mg or 5 mg |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 7 Participants |
| Age, Categorical Between 18 and 65 years | 24 Participants |
| Age, Continuous | 58.87 years STANDARD_DEVIATION 8.23 |
| Region of Enrollment United States | 31 participants |
| Sex: Female, Male Female | 13 Participants |
| Sex: Female, Male Male | 18 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 31 / 31 |
| serious Total, serious adverse events | 0 / 31 |
Outcome results
Primary
Tolerability of Isradipine Based on the Number of Participants That Complete the Study
Time frame: 1 year
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Isradipine 20mg, 15mg, 10mg or 5 mg | Tolerability of Isradipine Based on the Number of Participants That Complete the Study | 25 Participants |
Secondary
Change in Motor UPDRS Scores: Baseline vs. Final Visit
Baseline visit = Week 0 Final visit = Week 12 Unified Parkinson's Disease Rating Scale (UPDRS)is made up of the following sections: Part I: evaluation of Mentation, behavior, and mood Part II: self evaluation of the activities of daily life Part III: clinician-scored motor evaluation Part IV: Hoehn and Yahr stating of severity of Parkinson disease. Part V: Schwab and England ADL scale Only part three was used for this assessment. The higher the UPDRS score, the greater the disability from PD. The range for scores for Section III is 0 to 108.
Time frame: 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Isradipine 20mg, 15mg, 10mg or 5 mg | Change in Motor UPDRS Scores: Baseline vs. Final Visit | Baseline | 7.61 UPDRS Part III Score | Standard Deviation 3.01 |
| Isradipine 20mg, 15mg, 10mg or 5 mg | Change in Motor UPDRS Scores: Baseline vs. Final Visit | Final | 7.08 UPDRS Part III Score | Standard Deviation 2.68 |
Secondary
Number of Participants That Completed the Study at Each Dose Level of Isradipine
Time frame: 1 year
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Isradipine 20mg, 15mg, 10mg or 5 mg | Number of Participants That Completed the Study at Each Dose Level of Isradipine | 20mg | 16 Participants |
| Isradipine 20mg, 15mg, 10mg or 5 mg | Number of Participants That Completed the Study at Each Dose Level of Isradipine | 15mg | 4 Participants |
| Isradipine 20mg, 15mg, 10mg or 5 mg | Number of Participants That Completed the Study at Each Dose Level of Isradipine | 10mg | 4 Participants |
| Isradipine 20mg, 15mg, 10mg or 5 mg | Number of Participants That Completed the Study at Each Dose Level of Isradipine | 5mg | 1 Participants |
Secondary
Number of Participants That Tolerated Each Dose Level of Isradipine Between PD Patients Treated With Antihypertensive Agent and Not on Antihypertensive Agent
At the time of enrollment, some patients were currently being treated with antihypertensive agents including Propanolol, Toprol, Lisinopril, Diovan, Norvasc. HTN+: Participants on an antihypertensive agent HTN-: Participants not on an antihypertensive agent
Time frame: 1 year
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Isradipine 20mg, 15mg, 10mg or 5 mg | Number of Participants That Tolerated Each Dose Level of Isradipine Between PD Patients Treated With Antihypertensive Agent and Not on Antihypertensive Agent | HTN+ 20mg | 2 Participants |
| Isradipine 20mg, 15mg, 10mg or 5 mg | Number of Participants That Tolerated Each Dose Level of Isradipine Between PD Patients Treated With Antihypertensive Agent and Not on Antihypertensive Agent | HTN+ 15mg | 3 Participants |
| Isradipine 20mg, 15mg, 10mg or 5 mg | Number of Participants That Tolerated Each Dose Level of Isradipine Between PD Patients Treated With Antihypertensive Agent and Not on Antihypertensive Agent | HTN+ 10 mg | 1 Participants |
| Isradipine 20mg, 15mg, 10mg or 5 mg | Number of Participants That Tolerated Each Dose Level of Isradipine Between PD Patients Treated With Antihypertensive Agent and Not on Antihypertensive Agent | HTN+ 5mg | 0 Participants |
| Isradipine 20mg, 15mg, 10mg or 5 mg | Number of Participants That Tolerated Each Dose Level of Isradipine Between PD Patients Treated With Antihypertensive Agent and Not on Antihypertensive Agent | HTN- 20mg | 14 Participants |
| Isradipine 20mg, 15mg, 10mg or 5 mg | Number of Participants That Tolerated Each Dose Level of Isradipine Between PD Patients Treated With Antihypertensive Agent and Not on Antihypertensive Agent | HTN- 15mg | 2 Participants |
| Isradipine 20mg, 15mg, 10mg or 5 mg | Number of Participants That Tolerated Each Dose Level of Isradipine Between PD Patients Treated With Antihypertensive Agent and Not on Antihypertensive Agent | HTN- 10mg | 5 Participants |
| Isradipine 20mg, 15mg, 10mg or 5 mg | Number of Participants That Tolerated Each Dose Level of Isradipine Between PD Patients Treated With Antihypertensive Agent and Not on Antihypertensive Agent | HTN- 5mg | 4 Participants |
Secondary
Number of Participants That Tolerated Each Dose of Isradipine
Tolerability= maximum tolerated dose
Time frame: 1 year
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Isradipine 20mg, 15mg, 10mg or 5 mg | Number of Participants That Tolerated Each Dose of Isradipine | 20mg | 16 Participants |
| Isradipine 20mg, 15mg, 10mg or 5 mg | Number of Participants That Tolerated Each Dose of Isradipine | 15mg | 5 Participants |
| Isradipine 20mg, 15mg, 10mg or 5 mg | Number of Participants That Tolerated Each Dose of Isradipine | 10mg | 6 Participants |
| Isradipine 20mg, 15mg, 10mg or 5 mg | Number of Participants That Tolerated Each Dose of Isradipine | 5mg | 4 Participants |
Secondary
Pharmacokinetic Data - Mean Serum Concentration and Dosage Exposure Across the Dose Range of Isradipine
Mean Plasma Concentration (+/- SD ng/mL)
Time frame: 1 year
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Isradipine 20mg, 15mg, 10mg or 5 mg | Pharmacokinetic Data - Mean Serum Concentration and Dosage Exposure Across the Dose Range of Isradipine | 20 mg | 2.48 ng/mL | Standard Deviation 1.16 |
| Isradipine 20mg, 15mg, 10mg or 5 mg | Pharmacokinetic Data - Mean Serum Concentration and Dosage Exposure Across the Dose Range of Isradipine | 15 mg | 2.53 ng/mL | Standard Deviation 1.33 |
| Isradipine 20mg, 15mg, 10mg or 5 mg | Pharmacokinetic Data - Mean Serum Concentration and Dosage Exposure Across the Dose Range of Isradipine | 10 mg | 1.53 ng/mL | Standard Deviation 0.72 |
| Isradipine 20mg, 15mg, 10mg or 5 mg | Pharmacokinetic Data - Mean Serum Concentration and Dosage Exposure Across the Dose Range of Isradipine | 5 mg | 0.68 ng/mL | Standard Deviation 0.38 |
Secondary
Safety of the Standard Titration Schedule in PD Population as Measured by the Number of Patients That Are Able to Increase the Dose to 20 mg Daily
Time frame: 1 year
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Isradipine 20mg, 15mg, 10mg or 5 mg | Safety of the Standard Titration Schedule in PD Population as Measured by the Number of Patients That Are Able to Increase the Dose to 20 mg Daily | 16 Participants |